Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT03949283IIIPlatinum resistant ovarian cancerStandard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian CancerCA, FL, IN, LA, OH, OK, PA, WVView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitorApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT04729387IIIPlatinum resistant or refractory high grade serous or endometrioid ovarian cancer without germ-line BRCA1/2 mutationsEPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian CancerAZ, AR, FL, IL, MD, MA, NY, OH, SD, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AlpelisibPI3K inhibitor BYL719, BYL719, phosphoinositide 3-Kinase inhibitor BYL719, PiqrayPI3K alpha inhibitorApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT04729608IIIPlatinum resistant high grade serous ovarian cancer with no prior bevacizumab; no prior paclitaxel for platinum resistant diseaseA Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)AL, CA, CO, CT, FL, GA, IL, IN, KY, LA, ME, MD, MA, MI, MN, MO, MT, NV, NJ, NM, NY, NC, OH, OK, OR, PA, RI, SC, SD, TN, TX, VA, WA, WV, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Batiraxceptanti-AXL fusion protein AVB-S6-500, AVB-S6-500, AVB-500GAS6 antagonistClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT05092360IIIPlatinum resistant or refractory ovarian cancer that must have had prior bevacizumab (5 or less prior therapies for platinum resistant disease)A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)AZ, CA, FL, NJ, NY, NC, OH, OR, SC, SD, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Nemvaleukin alfaintermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230IL-2/IL-15R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05116189IIIPlatinum resistant ovarian cancer; 1-2 prior systemic therapiesA Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)CA, CT, FL, GA, IL, IN, KY, LA, MD, MA, NJ, NY, NC, OH, OR, PA, SD, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BevacizumabAvastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chainVEGF antagonistApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05257408IIIPlatinum resistant high grade serous or high grade endometrioid ovarian cancer that must have had prior bevacizumabA Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)SDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
RelacorilantRELA, CORT125134GR antagonistClinical Trials
NCT05281471IIIPlatinum resistant or refractory ovarian cancer that must have had prior bevacizumabA Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)FLView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BevacizumabAvastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chainVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
Olvimulogene nanivacirepveclight-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68, GL-ONC1Induces immune response and tumor cell lysisClinical Trials
NCT05243524IIbPlatinum resistant ovarian cancer; all lesions must be less than 4 cmPhase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects With Platinum-Resistant, Epithelial Ovarian Cancer.FL, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
Maveropepimut-Ssurvivin antigen vaccine DPX-Survivac, DPX-SurvivacImmune response against cancer expressing survivinClinical Trials
NCT02312245IIRecurrent ovarian cancerAvatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube CancersAZ, FL, MNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT02693535IIOvarian expansion for CDKN2A loss or mutation or ERBB2/ERBB3 amplification, mutation or over-expression, or high TMB or Advanced solid tumors with molecular alterations in AKT1, ALK, ATM, ATR, BRAF, BRCA1/2, CDK4/6 AMP, CDK12, CDKN2A, CHEK2, CSF1R, FANCA, FGFR1/2/3, FLT3, KIT, MRE11A, MLH1, MSH2, MSH6, NBN, NRG1, NTRK1/2/3 AMP, PALB2, PDGFR, PDGFRB, PMS2, POLD1, POLE, RAF-1, RAD51C, RET, ROS1, TSC1/2, VEGFR, or with high MSI, high TMB, HRD+, or LOHhiTargeted Agent and Profiling Utilization Registry (TAPUR) StudyAL, AZ, CA, CT, FL, GA, HI, IL, IN, ME, MI, NE, NH, NM, NY, NC, ND, OH, OR, PA, SC, SD, TN, TX, UT, VA, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
AfatinibBIBW 2992 MA2, Gilotrif, Afatinib dimaleateEGFR, HER2, HER4 kinase inhibitorApproved in Other Cancers
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
Crizotinibc-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkoric-Met and ALK kinase inhibitorApproved in Other Cancers
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
LarotrectinibTrk inhibitor LOXO-101, LOXO-101, Vitrakvipan-Trk kinase inhibitorApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitorApproved in Other Cancers
PHESGOpertuzumab, trastuzumab, and hyaluronidase-zzxfHER2 antagonistApproved in Other Cancers
RegorafanibBAY73-4506, multikinase inhibitor BAY 73-4506, StivargaMulti-targeted RTK inhibitorApproved in Other Cancers
SunitinibSutent, Sunitinib malateVEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibitApproved in Other Cancers
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
TemsirolimusTorisel, CCI-779mTOR inhibitorApproved in Other Cancers
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonistApproved in Other Cancers
TucatinibIrbinitinib, ONT-380HER2 kinase inhibitorApproved in Other Cancers
NCT02465060IIExpansion for BRAF V600E or V600K (except low grade serous), or advanced LAG-3+ solid tumors with high MSIMolecular Analysis for Therapy Choice (MATCH)AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DabrafenibGSK-2118436A, BRAF inhibitor GSK2118436, GSK2118436, TafinlarBRAF kinase inhibitorApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RelatlimabBMS986016, Anti-LAG-3 monoclonal antibody BMS-986016, Anti-LAG-3 monoclonal antibody BMS-986016Blocks LAG-3 inhibition of T cellsClinical Trials
TrametinibMekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212MEK1/2 inhibitorApproved in Other Cancers
NCT02628067IIAdvanced solid tumors with high MSI or high TMBA Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)CA, FL, MA, NJView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT02873962IIPartially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients cannot be BRCA1/2 mutated)A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal CancerMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BevacizumabAvastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chainVEGF antagonistApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RucaparibRubraca, CO-338, PF 01367338, AG-014699PARP inhibitorApproved in Ovarian Cancer
NCT01851369IIGranulosa cell ovarian cancerA Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and LymphomasMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MethoxyamineTRC102Base excision repair inhibitorClinical Trials
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agentApproved in Other Cancers
NCT02364713IIPlatinum resistant, refractory or persistent ovarian cancer (no measurable disease outside the peritoneal cavity)MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal CancerAZ, FL, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MV-NISoncolytic measles virus encoding thyroidal sodium iodide symporterInduces immune response and tumor cell lysisClinical Trials
NCT02675829IIAdvanced solid tumors with HER2 amplificationA Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant CancersNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Trastuzumab emtansinetrastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansineADC: anti-HER2 + microtubule destabilizer (DM1)Approved in Other Cancers
NCT02834013IIAdvanced ovarian small cell cancerDART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsAL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03026062IIPlatinum resistant or refractory clear cell ovarian cancer or mixed epithelial carcinoma with a clear cell componentRandomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian CancerTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
TremelimumabTicilimumab, CP-675206, CP-675,206, CP-675, anti-CTLA4 human monoclonal antibody CP-675,206Blocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NCT03212274IIAdvanced solid tumors with IDH1 or IDH2 mutationsA Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid TumorsCA, CT, FL, KS, MD, MA, MO, NH, NJ, NY, NC, OH, OK, PA, TN, TX, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03310879IIAdvanced solid tumors with CCND1/2/3 alterations or CDK4/6 amplificationsA Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6MAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
NCT03355976IIRecurrent clear cell ovarian cancerBrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasIL, RIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03412877IIAdvanced solid tumorsA Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic CancerMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2 receptor agonistApproved in Other Cancers
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
Individual Patient TCR-Transduced PBLautologous PBLs retrovirally-transduced with TCRs targeting neoantigensImmune response against neoantigensClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03428802IIAdvanced solid tumors with high MSI and with POLE, POLD, or BRCA1/2 mutationsA Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic InstabilityNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03462342IIPlatinum sensitive high grade serous ovarian cancer (cohort A), or platinum sensitive high grade serous ovarian cancer with BRCA1/2 mutations or HRD+ w/ clinical benefit of PARPi therapy followed by progression in most recent prior regimen (cohort DII)Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian CancerMD, MA, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03579316IIPlatinum sensitive ovarian cancer with BRCA1/2 mutations or HRD+ that must have benefited from and then progressed on prior PARP inhibitorEFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP InhibitionMA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03682289IIAdvanced solid tumors with ARID1A or ATM alterationsPhase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor MalignanciesCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03693014IIAdvanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatmentA Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeCT, NJ, NY, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyIrradiation, Radiotherapy
NCT03574779IIPlatinum resistant ovarian cancer or Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant)A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL)CA, IL, MA, MN, OK, SDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BevacizumabAvastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chainVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
DostarlimabTSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NiraparibZejula, MK4827PARP inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT03732950IIRecurrent ovarian cancerA Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression ProfilingCA, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03734692IIPlatinum sensitive ovarian cancer with first or second recurrence in peritoneal cavitySystemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RintatolimodAtvogenTLR3 agonist and immune cell stimulatorApproved in Other Indications
NCT03673124IIRecurrent low grade serous ovarian cancerA Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or PeritoneumCA, FL, GA, IL, IN, MI, MN, NH, NJ, NM, OH, OK, PA, RI, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitorApproved in Other Cancers
NCT03742895IIAdvanced solid tumors without BRCA1/2 mutations, with Homologous Recombination Repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced CancerMD, NE, NJ, NY, SD, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT03878849IIRecurrent ovarian cancerPhase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®OKView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
StenoparibPARP/Tankyrase inhibitor 2X-121, E7449, 2X-121PARP inhibitorClinical Trials
NCT01174121IIAdvanced solid tumorsA Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of PembrolizumabMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2 receptor agonistApproved in Other Cancers
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Selected Young TILImmune response against tumor-associated antigensClinical Trials
NCT03909152IIRecurrent PR+ granulosa cell ovarian cancerBasket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor), Alone or In Combination With Anastrozole in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial CancerNJ, NYView Drugs View Results